医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The U.S.-India Business Council Expresses Unease Over Supreme Court of India’s Ruling on Novartis Glivec Case: Seeks Reassurance for Investors

2013年04月03日 AM02:40
このエントリーをはてなブックマークに追加


 

NEW DELHI

A decision was issued today by the Supreme Court of India, which denied a patent on Glivec, an innovative cancer medication produced by pharmaceutical company Novartis. The court’s decision cites Section 3 (d) of India’s patent law and states that a patentee must prove enhanced efficacy of a medicine in order to obtain a patent in India.

Over 40 countries including China, Russia, and Taiwan have already granted a patent for Novartis’ Glivec and India now stands out as unique for not granting a patent to this incremental innovation. The denial of the Glivec patent may now exclude from patentability many other significant inventions in the pharmaceuticals area.

U.S.-India Business Council (USIBC) President Ron Somers stated, “Innovation requires the reward and protection of intellectual property. We are certain India’s leadership understands this, and that creating and maintaining an environment that inspires and enables innovation is in India’s ultimate, long-term interest. Such an environment is crucial if India is to attract investment in this or other highly complex sectors.”

“As India declares this the ‘decade of innovation,’ we hope that the government of India will implement policies and practices that promote innovation, fostering an environment that encourages India’s smartest minds to produce new cures and treatments, as well as original technologies in other sectors,” said Somers. “We believe that incremental innovation is an area where India has a lot to offer and, in particular, where its robust generics business can start to take positive steps towards innovation by improving on therapies that already exist. We recognize the importance of generics to the contribution of health once patents expire, but believe that in order for India to become the ‘innovation nation of the 21st century,’ it should reward and encourage innovation, including incremental innovation, by respecting the significant resources and costs associated with finding new and better cures to treat diseases.”

The U.S.-India Business Council was formed in 1975 at the request of the United States and Indian governments to advance two-way trade and deepen commercial ties. Today, USIBC is the premier business advocacy association comprised of nearly 400 of America’s and India’s top companies dedicated to enhancing the U.S.-India commercial relationship. Ajay Banga, President and CEO of MasterCard, serves as chairman of USIBC.

www.usibc.com

CONTACT

U.S.-India Business Council
Kathryn Van Dyken, 202-463-5768
kvandyken@uschamber.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Walmart, JD.com, IBM and Tsinghua University Launch a Blockchain Food Safety Alliance in China
  • ADCセラピューティクスが当社の新規抗体薬物複合体ADCT-402の第I相中間データを発表
  • Vedanta Biosciences Granted Four New U.S. Patents Expanding Coverage for Compositions and Methods of Use for Therapeutics Based on Microbiome-Derived Bacterial Consortia
  • Daiichi Sankyo and Puma Biotechnology Announce Research Collaboration with Major Cancer Center in HER2-Mutated Cancer
  • 武田和Seattle Genetics呈报3期ECHELON-1临床试验的阳性数据,该试验评估ADCETRIS® (brentuximab vedotin)用于晚期霍奇金淋巴瘤的一线治疗